Atlas Trials

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Clinical trial NCT05265962 · UNKNOWN

Trial details

NCT number
NCT05265962
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2022-12-01
Primary completion
2023-12-31
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.